Jesper Brandgaard joined Novo Nordisk in 1999 as senior vice president of Corporate Finance and was appointed executive vice president and chief financial officer in November 2000. As chief financial officer, Mr Brandgaard is responsible for a number of functions including finance, legal, procurement and investor relations. In addition, Mr Brandgaard is overall responsible for the Biopharm activities. Mr Brandgaard serves as chairman of the board of SimCorp A/S, Denmark, and is a member of the Board of Chr. Hansen A/S, Denmark. Mr Brandgaard has an MSc in Economics and Auditing from 1990 as well as an MBA from 1995, both from the Copenhagen Business School, Denmark. Mr Brandgaard is a Danish national, born October 1963.   Jesper Brandgaard joined Novo Nordisk in 1999 as senior vice president of Corporate Finance and was appointed executive vice president and chief financial officer in November 2000. As chief financial officer, Mr Brandgaard is responsible for a number of functions including finance, legal, procurement and investor relations. In addition, Mr Brandgaard is overall responsible for the Biopharm activities. Mr Brandgaard serves as chairman of the board of SimCorp A/S, Denmark, and is a member of the Board of Chr. Hansen A/S, Denmark. Mr Brandgaard has an MSc in Economics and Auditing from 1990 as well as an MBA from 1995, both from the Copenhagen Business School, Denmark. Mr Brandgaard is a Danish national, born October 1963.  

Pathology